We aim to improve the lives of patients with ocular surface disease (OSD) with our pioneering platelet-derived regenerative biologic (PRB) therapy.
Stellular has proven the efficacy of PRB in animal models and has established scalable manufacturing methods that will enable clinical trials and commercial production.
We are pursuing initial clinical proof of concept in Sjogren's syndrome-related dry eye and are poised to expand rapidly into the broader OSD market.
Combining the regenerative potential of platelet-rich plasma (PRP) with the advantages of an engineered product
Complex, common, and on the rise
At Stellular we are quickly advancing our programs to provide more and better treatment options for patients with OSD.
Email us for career opportunities